Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.

Mocroft, Amanda; Lundgren, Jens; Gerstoft, Jan; Rasmussen, Line D; Bhagani, Sanjay; Aho, Inka; Pradier, Christian; Bogner, Johannes R; Mussini, Christina; Uberti Foppa, Caterina; Maltez, Fernando; Laguno, Montse; Wandeler, Gilles; Falconer, Karolin; Trofimova, Tatyana; Borodulina, Elena; Jevtovic, Djordje; Bakowska, Elzbieta; Kase, Kerstin; Kyselyova, Galina; ... (2019). Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. (In Press). Clinical infectious diseases Oxford University Press 10.1093/cid/ciz601

[img] Text
Wandeler.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (412kB) | Request a copy

BACKGROUND A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. METHODS People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). RESULTS There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. CONCLUSIONS Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Wandeler, Gilles

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1537-6591

Publisher:

Oxford University Press

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

18 Sep 2019 15:34

Last Modified:

18 Sep 2019 15:34

Publisher DOI:

10.1093/cid/ciz601

PubMed ID:

31504296

Uncontrolled Keywords:

HIV cardiovascular disease end-stage liver disease hepatitis C malignancies

BORIS DOI:

10.7892/boris.133233

URI:

https://boris.unibe.ch/id/eprint/133233

Actions (login required)

Edit item Edit item
Provide Feedback